Phase i trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6902-6911

  Meyer, Janelle M ^a   Perlewitz, Kelly S ^b   Hayden, James B ^c   Doung, Yee Cheen ^c   Hung, Arthur Y ^c   Vetto, John T ^c   Pommier, Rodney F ^c   Mansoor, Atiya ^c   Beckett, Brooke R ^c   Tudorica, Alina ^c   Mori, Motomi ^c   Holtorf, Megan L ^c   Afzal, Aneela ^c   Woodward, William J ^c   Rodler, Eve T ^d   Jones, Robin L ^d   Huang, Wei ^c   Ryan, Christopher W ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Providence Cancer Center   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; EPIRUBICIN; GADOTERIDOL; HEMOGLOBIN; IFOSFAMIDE; SORAFENIB;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN DISEASE; CATHETER THROMBOSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTRAST ENHANCEMENT; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FRACTURE; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE; LIMB SALVAGE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHASE 1 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; SINUS TACHYCARDIA; SOFT TISSUE SARCOMA; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; TUMOR NECROSIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOICE CHANGE; VOMITING; WOUND COMPLICATION;

ADULT; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREOPERATIVE PERIOD; SARCOMA; YOUNG ADULT;

EID: 84890620348     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1594     Document Type: Article

References (32)

1. Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer 1975;35:1478-83.
2. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft tissue sarcomas. Cancer 1981;47:2391-7. (Pubitemid 11127627)
3. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203. (Pubitemid 28041599)
4. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003;21:2719-25. (Pubitemid 46606317)
5. Herbert SH, Corn BW, Solin LJ, Lanciano RM, Schultz DJ, McKenna WG, et al. Limb-preserving treatment for soft tissue sarcomas of the extremities. The significance of surgical margins. Cancer 1993;72: 1230-8. (Pubitemid 23224991)
6. Ryan CW, Montag AG, Hosenpud JR, Samuels B, Hayden JB, Hung AY, et al. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer 2008;112:2432-9.
7. Eilber F, Eckardt J, Rosen G, Forscher C, Selch M, Fu YS. Preoperative therapy for soft tissue sarcoma. Hematol Oncol Clin North Am 1995;9:817-23.
8. Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann Surg Oncol 1994;1: 18-27.
9. Franklin WA, Christison WH, Colley M, Montag AG, Stephens JK, Hart CE. In situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res 1990;50:6344-8. (Pubitemid 20323698)
10. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 2001;13:261-9. (Pubitemid 32578992)
11. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
12. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-40.
13. von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012;118:770-6.
14. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42. (Pubitemid 47492947)
15. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
16. Wadlow RC, Ryan DP. The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 2010;116:3537-48.
17. Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012;11:45-52.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32. (Pubitemid 29463104)
20. Li X, Rooney WD, Springer CS Jr. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med 2005;54:1351-9. (Pubitemid 41740764)
21. Yankeelov TE, Rooney WD, Li X, Springer CS Jr. Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med 2003;50: 1151-69. (Pubitemid 37494016)
22. Huang W, Li X, Morris EA, Tudorica LA, Seshan VE, Rooney WD, et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors invivo. Proc Natl Acad Sci USA 2008;105:17943-8.
23. Huang W, Tudorica LA, Li X, Thakur SB, Chen Y, Morris EA, et al. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging. Radiology 2011;261:394-403.
24. Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, et al. Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. Magn Reson Med 2013;69:171-8.
25. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235-41. (Pubitemid 34717977)
26. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006;66:8770-8. (Pubitemid 44449194)
27. DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:1117-27. (Pubitemid 36794046)
28. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95: 1120-6. (Pubitemid 34925365)
29. Pisters PW, Patel SR, Varma DG, Cheng SC, Chen NP, Nguyen HT, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:3481-7. (Pubitemid 27527721)
30. Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS, et al. Preoperative chemotherapy for soft tissue sarcomas of the extremities. Ann Surg 1990;211:476-81. (Pubitemid 20138190)
31. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012;9:167-77.
32. Tudorica A OK, Chui SYC, Roy N, Troxell ML, Chen Y, Naik A, et al. Early prediction of breast cancer therapeutic response and evaluation of residual disease using quantitative DCE-MRI. Proc Intl Soc Magn Reson Med 2013;21:504.